Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AQUAPHYLLIN vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Maintenance treatment of asthma,Chronic obstructive pulmonary disease (COPD) exacerbations
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4 and CYP2E1.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: 85-95%; intramuscular: 75-90%.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No adjustment required.
No data; not applicable.
In Child-Pugh Class B or C, reduce dose by 50% and monitor serum theophylline levels.
No data; not applicable.
Loading dose: 5 mg/kg orally. Maintenance: 4 mg/kg orally every 6 hours for children 1-9 years; 3 mg/kg orally every 6 hours for children 10-16 years. Maximum daily dose: 24 mg/kg.
No data; not applicable.
Use lower initial dose (e.g., 200 mg orally every 8 hours) and titrate slowly; monitor serum theophylline levels due to decreased clearance.
No data; not applicable.
None
None
Cardiovascular events: arrhythmias, tachycardia, hypotension,Seizures in patients with history of seizure disorder,Significant drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin),Overdose risk: narrow therapeutic index, monitor serum levels
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or other xanthines,Active seizure disorders (relative),Uncontrolled cardiac arrhythmias
Hypersensitivity to arformoterol or any component of the formulation
Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase theophylline levels and risk of toxicity. High-protein, low-carbohydrate diets may decrease theophylline metabolism; low-protein, high-carbohydrate diets may increase metabolism. Consistent dietary habits are recommended. Charcoal-broiled meats may increase metabolism.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea, tachycardia, and jitteriness due to transplacental passage. Maternal toxicity at high doses may cause fetal hypoxia.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted in breast milk with M/P ratio approximately 0.6-0.7. Infant plasma levels may reach 10-50% of maternal levels. Monitor infant for irritability, insomnia, and feeding difficulties. Use caution and consider alternative agents if infant is premature or has cardiovascular disease.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy increases theophylline clearance by 30-50% due to increased hepatic metabolism and renal perfusion. Dose may need to be increased by 30% to maintain therapeutic levels (5-15 mcg/m L). Monitor serum levels frequently and adjust accordingly.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Aquaphyllin (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L for optimal bronchodilation. Monitor for toxicity (nausea, vomiting, tremor, tachycardia) especially in patients with hepatic impairment, heart failure, or concurrent use of CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Smoking induces theophylline metabolism requiring higher doses. Use with caution in elderly and patients with seizure disorders.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine-containing foods or beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity such as persistent nausea, vomiting, rapid or irregular heartbeat, or seizures immediately.,Do not stop taking this medication abruptly; taper under medical supervision.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,If you smoke, tell your doctor; changes in smoking habits may require dose adjustment.,Store at room temperature away from moisture and heat.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AQUAPHYLLIN vs AEROLONE, answered by our medical review team.
AQUAPHYLLIN is a Bronchodilator that works by Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AQUAPHYLLIN and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AQUAPHYLLIN is: 300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AQUAPHYLLIN and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AQUAPHYLLIN is classified as Category C. Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.